Background: Lymph node metastasis (LNM) from Breast cancer (BC) is commonly seen in BC progression. Currently, the identification of genes linked with LNM in BC remains in mystery. Methods: Genes related to BC LNM were screened, and a risk model was constructed based on LASSO-Cox analysis. Combined with the Kaplan-Meier curve, the ability of riskscore to distinguish different baseline characteristics was evaluated, and model was verified by the receiver operating characteristic (ROC) curve. The expression levels of prognostic marker genes were analyzed by qRT-PCR and western blot (WB). Results: A higher survival rate and longer survival time in low-risk BC patients. The 1, 3 and 5 year AUC values of the training set were 0.79, 0.74, and 0.73, respectively. Results for the validation set was similar to the training set. The differentially expressed genes between the high- and low-risk groups were significantly enriched in immune pathways. In addition, the low-risk group had higher levels of immune infiltration. qRT-PCR and WB results showed that in BC, CDH10, SMR3A, POU3F2, and FABP7 were down-regulated, and LHX1 was upregulated. Conclusions: We built a prognostic model of BC based on LNM-related genes, proffering evaluation for prognosis and precise cure of BC. Significance: At present, the genes related to lymph node metastasis in BC are still largely unknown and need to be further explored. Searching for potential lymph node metastasis-related genes of BC will provide meaningful biomarkers for BC treatment. Based on TCGA-BRCA data, we established an effective 11-gene prognostic risk model that could predict patient outcomes independently. Our model could classify BC patients and distinguish patients with poor prognosis effectively. Besides, the feature genes we identified might exert a predictive function in immunotherapy. The results of this study provide a new reference for the prognosis and treatment of BC patients with lymph node metastasis.

乳腺癌已经成为全球最为常见的女性癌症,其治疗方式以手术为主.传统乳腺手术因手术切口大、并发症多且较为严重而影响患者的生存质量,在不断追求微创手术的今天已经不能满足女性美观的需求.腔镜手术的发展以及设备的迭代使乳腺癌腔镜手术成为可能,溶脂法和非溶脂法建腔技术的出现和完善为乳腺癌腔镜手术的开展奠定基础,其中短期疗效的安全性令人鼓舞.手术技术不断完善,各种共识及推荐指南的发布进一步降低学习成本,利于乳腺腔镜技术的进一步推广及发展.我国单孔腔镜和机器人辅助乳腺手术的出现标志乳腺腔镜技术的进一步发展,迈入国际领先行列.该文就乳腺癌腔镜手术的相关研究进展进行综述.

目的 探讨单孔腔镜保留乳头乳晕全乳切除术在早期乳腺癌中的应用效果.方法 选取 2021 年7 月至2022 年8 月于广西壮族自治区人民医院行保留乳头乳晕全乳切除术的40 例患者,其中行单孔腔镜下保留乳头乳晕全乳切除术者20 例(腔镜组),开放保留乳头乳晕全乳切除术者 20 例(开放组).比较两组手术时间、术中出血量、切口长度、术后住院时间、术后引流量、并发症发生率,以及术后6 个月的乳腺癌生存质量测评量表(FACT-B)评分和美容效果满意度评分等.结果 两组患者均顺利完成手术并康复出院.腔镜组切口长度短于开放组,但手术时间长于开放组,术后引流量多于开放组,差异有统计学意义(P＜0.05).腔镜组术后6 个月FACT-B测评量表评分和美容效果满意度评分高于开放组,差异有统计学意义(P＜0.05).两组术中出血量、术后住院时间、术后并发症发生率比较差异无统计学意义(P＞0.05).结论 单孔腔镜下保留乳头乳晕全乳切除术安全有效,具有更好的美容效果和患者满意度,可提高患者的生活质量和心理健康.

BackgroundThe lncRNA HOTAIR is frequently overexpressed in breast cancer tissues and plays an important role in the development of breast cancer. Here, we investigated the effect of the lncRNA HOTAIR on the biological behaviour of breast cancer cells and its molecular mechanism.MethodsWe investigated the level of HOTAIR in breast cancer and its clinical pathological characteristics by bioinformatic methods. Then, we evaluated the effects of HOTAIR and miRNA-1 expression on the biological behaviour of breast cancer cells by qPCR, Cell Counting Kit-8 (CCK-8) assay, clonogenic assays, Transwell assay and flow cytometry for cell proliferation, invasion migration and apoptosis, and cell cycle analysis. Finally, the target genes of the lncRNA HOTAIR/miR-1/GOLPH3 regulatory axis were validated by luciferase reports.ResultsThe expression of HOTAIR in breast cancer tissues was significantly higher than that in normal breast tissues (P < 0.05). Silencing of HOTAIR suppressed cell proliferation, invasion and migration, promoted apoptosis and induced G(1) phase block in breast cancer (P < 0.0001). We also verified that miR-1 is a target of HOTAIR and that GOLPH3 is a target of miR-1 by luciferase reporter assays (P < 0.001).ConclusionsThe expression of HOTAIR was significantly elevated in breast cancer tissues. Reducing the expression of HOTAIR inhibited the proliferation, invasion and migration of breast cancer cells and promoted apoptosis, and the mechanism was mainly the effect of the lncRNA HOTAIR/miR-1/GOLPH3 regulatory axis on the biological behaviour of breast cancer cells.

目的 探讨行全乳切除术且伴1～2枚前哨淋巴结(SLN)宏转移的乳腺癌患者发生非前哨淋巴结(NSLN)转移的危险因素.方法 收集158例行全乳切除术伴1～2枚SLN宏转移并进一步行腋窝淋巴结清扫术的乳腺癌患者的临床病理资料.采用多因素Logistic回归模型分析患者发生NSLN转移的危险因素,采用受试者工作特征曲线评估影响因素诊断患者发生NSLN转移的效能.结果 158例患者中,共59例(37.34％)患者发生NSLN转移.与NSLN阴性患者相比,NSLN阳性患者的肿瘤直径更大,宏转移SLN比值更高,阴性SLN数更少,脉管侵犯率更高(均P<0.05).多因素Logistic回归模型分析结果显示,肿瘤直径较大、宏转移SLN比值较高及伴脉管侵犯是行全乳切除术伴1～2枚SLN宏转移的乳腺癌患者发生NSLN转移的危险因素(均P<0.05).受试者工作特征曲线分析结果显示,肿瘤直径为22 mm、宏转移SLN比值为0.33时,其诊断全乳切除术伴1～2枚SLN宏转移的乳腺癌患者发生NSLN转移的曲线下面积分别为0.660和0.650(均P<0.05).结论 全乳切除术伴1～2枚SLN宏转移的乳腺癌患者有较高的NSLN转移率,其中肿瘤直径较大、宏转移SLN比值较高、有脉管侵犯的患者发生NSLN转移的风险增加.

目的:在乳腺癌腋窝前哨淋巴结活检(SLNB)中,比较亚甲蓝不同浓度、不同注射部位对于前哨淋巴结(SLN)检出率的影响.方法:第一阶段:收集接受SLNB的111例乳腺癌患者,随机分为4组.分别使用不同浓度亚甲蓝(原液组、0.4％组、0.1％组、0.05％组)进行SLNB,对比各组与原液组间SLN检出率差异.第二阶段:收集接受SLNB的40例乳腺癌患者,随机分为2组.在不同部位(乳晕组、瘤周组)注射亚甲蓝进行SLNB,对比两组间SLN检出率差异.结果:原液组、0.4％组、0.1％组、0.05％组的检出率分别为

Background: Overweight and obesity have become a major health issue in the past 30 years. Several studies have already shown that obesity is significantly associated with a higher risk of developing breast cancer. However, few studies have assessed the prognostic value of the body mass index (BMI) in Asian populations. The purpose of this study was to retrospectively analyze the impact of BMI on the prognosis of breast cancer in overweight, under 160 cm tall patients from southern China. Methods: We retrospectively analyzed data from 525 breast cancer patients diagnosed between 2003 to 2010 in a multi-center of China. After applying the exclusion criteria, 315 patients with complete data were retained. Their clinical and pathological characteristics were compared using the chi-square test. Survival analysis was performed with the Kaplan-Meier method. Univariate and multivariate analyses were performed using Cox regression to calculate hormone receptor status, HER-2 status, lymph node status, age, BMI and tumor size hazard ratio (FIR), and 95% confidence intervals (95% CI). Results: There was a strong correlation between BMI and age in the baseline feature analysis (P=0.001). After grouping the patients according to the molecular type of cancer, we found that in Luminal A and B, the BMI was related to age (P=0.002, P=0.010). The disease-free survival (DFS) and overall survival (OS) of patients with different BMI were not significantly different. This conclusion was also reached by pairwise comparison of subgroups. There was no significant difference in recurrence in patients from different BMI groups. We did not find a critical weight threshold associated with higher risk of recurrence. There were no statistically significant differences in treatment among the three BMI groups of overweight patients. Conclusions: We found that the BMI of Chinese breast cancer patients is related to age but not prognosis.

Breast cancer (BC) is a common malignant tumor in women, and a considerable number of studies show that aberrant expression of miRNA is correlated with BC development. By analyzing TCGA-BRCA database through bioinformatics method, this study disclosed that miR-337 3p was significantly low in BC tissue and might be a cancer inhibitor in BC. To explore the effect and potential mechanism of miR-337 3p in BC, qRT-PCR was used in this study to indicate that the expression of miR-337 3p was downregulated in BC cells. Then, the effects of miR-337 3p on BC cells were detected by western blot, Cell Counting Kit-8 (CCK-8), wound healing and Transwell assays. After upregulating miR-337 3p expression, the cell viability, migration, invasion and epithelial-mesenchymal transition (EMT) of BC cells were markedly inhibited while cell apoptosis remarkably increased. Besides, it was predicted and identified by bioinformatics analysis and dual-luciferase assay that ESRP1 was a target gene of miR-337 3p. Finally, the progression and EMT of BC cells were promoted after upregulating ESRP1 expression level. However, upregulating miR-337 3p as well as ESRP1 reduced the promotion on the malignant phenotype of BC cells. This result revealed that miR-337 3p could inhibit ESRP1 expression to perform its biological functions. In conclusion, it was illustrated in this study that miR-337 3p is a tumor-inhibitor of BC and plays its regulatory role via its downstream gene ESRP1.

目的 探讨miRNA-21(miR-21)对HER-2阳性乳腺癌生物学特性以及血管生成的影响.方法 收集HER-2阳性乳腺癌标本,通过PCR分析miR-21的表达,通过CCK8和Transwell实验验证增殖和侵袭能力,通过Western blotting实验验证VEGF表达变化.结果 miR-21在HER-2阳性乳腺癌中过表达(P<0.001),但其过表达不会影响预后(在所有乳腺癌患者中P=0.47,在HER-2阳性乳腺癌患者中P=0.26).抑制miR-21表达可抑制HER-2阳性乳腺癌的增殖(P<0.01)和侵袭(P<0.001),并且抑制miR-21的表达可抑制血管生成因子VEGF的表达.结论 癌基因miR-21在调控HER-2阳性乳腺癌生物学行为以及血管生成中发挥一定作用.

Researches establish an indispensable role of mitochondrial dysfunction in septic cardiomyopathy. We aimed to investigate the effects of long noncoding RNA (LncRNA) SOX2 overlapping transcript (SOX2OT) on mitochondrial dysfunction in septic cardiomyopathy. We observed an obvious overexpression of SOX2OT in septic hearts and cardiomyocytes. Knockdown of SOX2OT in mice recovered the reduced cardiac function, and improved the mitochondrial membrane potential impaired by lipopolysaccharide (LPS). SOX2OT overexpressed mice showed the opposite situation. In parallel, knockdown of SOX2OT in cardiomyocytes restored the mitochondrial membrane potential, along with reduced mitochondrial reactive oxygen species production induced by LPS, while overexpression of SOX2OT reversed these effects. Mechanistically, SOX2OT could regulate mitochondrial dysfunction in septic cardiomyopathy via SOX2. In general, SOX2OT contributed to mitochondrial dysfunction progression via inhibiting SOX2 expression in septic cardiomyopathy, which may provide a new insight for treatment of septic cardiomyopathy.